MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes)

Overview and Mitochondrial Genetics
The m.3243A>G Mutation and Heteroplasmy
Stroke-Like Episodes: The Defining Feature
Full Clinical Spectrum
MIDD: Maternally Inherited Diabetes and Deafness
Diagnosis
Treatment: Mitochondrial Cocktail and L-Arginine
Prognosis and Living with MELAS
Key Research Papers
Featured Videos
Connections

Overview and Mitochondrial Genetics

MELAS syndrome — mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes — is the most common maternally inherited mitochondrial disease. The name captures the three hallmark features that originally defined the syndrome when it was first described in 1984: brain dysfunction (encephalomyopathy), dangerously elevated lactic acid (lactic acidosis), and brain events that look like strokes but arise from an entirely different mechanism. Every cell in your body contains hundreds to thousands of mitochondria, the tiny structures that convert food and oxygen into the cellular energy currency ATP. When mitochondria malfunction, the tissues that consume the most energy — brain, muscle, and heart — suffer first and most severely.

The underlying cause in roughly 80 percent of MELAS cases is a single-letter change in mitochondrial DNA: a mutation at position 3243 that swaps an adenine for a guanine (written as m.3243A>G). This mutation sits in the gene encoding a transfer RNA molecule that the mitochondrion needs to build its own proteins. When this tRNA is defective, the entire mitochondrial protein-synthesis machinery slows down, and the respiratory chain complexes — the molecular engines that generate ATP — cannot be assembled correctly. The result is an energy deficit that is felt most acutely wherever the metabolic demand is highest.

One important piece of context for patients and families: MELAS is not as rare as many assume. The m.3243A>G mutation itself is found in approximately 1 in 400 people in the general population, making it one of the most common inherited genetic variants. However, most people who carry this mutation at low proportions experience only mild symptoms — such as diabetes, hearing loss, or mild exercise intolerance — or no symptoms at all. Full MELAS syndrome, with stroke-like episodes and encephalomyopathy, is estimated to affect roughly 1 in 4,000 to 1 in 15,000 people. This spectrum of severity is explained by a phenomenon called heteroplasmy, which is discussed in detail in the next section.

The m.3243A>G Mutation and Heteroplasmy

Unlike the nuclear DNA you inherit from both parents, mitochondrial DNA is inherited exclusively from your mother. Every mitochondrion comes from the cytoplasm of the egg cell; sperm contribute almost no mitochondria at fertilization. This means that MELAS and all other mitochondrial DNA disorders follow a strictly maternal inheritance pattern: affected mothers transmit the mutation to all of their children, boys and girls alike, but affected fathers cannot pass it on to any of their children. If your mother has the m.3243A>G mutation, all of her siblings on her mother's side, and all of her children, are at risk of carrying it.

The concept that makes mitochondrial genetics uniquely complex is heteroplasmy. Each human cell contains hundreds to thousands of mitochondria, and each mitochondrion carries multiple copies of the 16,569-base-pair circular mitochondrial genome. When a mutation like m.3243A>G is present, some copies of the mitochondrial genome carry the mutation and some do not. The proportion of mutant copies — the heteroplasmy level — can range from near zero to 100 percent. Critically, this proportion varies between tissues in the same person, between cells in the same tissue, and between different members of the same family. A mother may carry 15 to 20 percent mutant load in her blood cells and feel relatively well, while her child inherits 70 to 80 percent mutant load and develops severe MELAS. The threshold above which clinical disease typically appears is roughly 60 to 70 percent mutant heteroplasmy, though this threshold is not absolute.

Heteroplasmy also changes over a lifetime in ways that matter clinically. Blood cells selectively lose mutant mitochondria over time, so a blood test in a middle-aged adult may significantly underestimate the true mutant burden. Urine epithelial cells are less affected by this drift and are preferred for detecting the mutation in adults. Muscle tissue retains the highest mutant load and is considered the gold standard for measuring heteroplasmy, which is one reason muscle biopsy remains an important diagnostic tool. Beyond the m.3243A>G mutation, two other MT-TL1 changes — m.3271T>C and m.3252A>G — account for a small fraction of MELAS cases. Separately, mutations in nuclear-encoded mitochondrial maintenance genes such as POLG1 (which encodes the mitochondrial DNA polymerase), POLG2, the TWNK helicase, and RRM2B can cause MELAS-like syndromes through autosomal recessive inheritance. These nuclear-gene cases are critically important to identify because they carry a 25 percent recurrence risk for each sibling — very different from the maternal inheritance of classic MELAS — and they require genetic counseling accordingly.

Stroke-Like Episodes: The Defining Feature

The stroke-like episodes of MELAS are the most dramatic and defining feature of the syndrome, and understanding that they are not true strokes is essential for proper management. In an ordinary ischemic stroke, a blood vessel is blocked and the brain tissue it supplies dies because it receives no oxygen. In MELAS, the blood vessels themselves are usually open; instead, local regions of brain cortex temporarily fail to produce enough energy to maintain their normal electrical activity. This metabolic failure triggers a cascade — glutamate excitotoxicity, cortical spreading depression, and vasogenic edema — that produces neurological symptoms nearly identical to a stroke but through an entirely different mechanism.

On MRI, this difference is visible to an informed radiologist. True ischemic strokes produce T2/FLAIR signal changes that respect vascular territories — they stay within the region supplied by one artery. MELAS stroke-like lesions cross vascular boundaries. They tend to cluster in the posterior cortex, particularly the occipital and parietal lobes, and they shift and migrate over serial imaging in ways no vascular event ever does. The cortex shows restricted diffusion, but it differs from the cytotoxic edema of true infarction. These lesions often partially or fully resolve between episodes on MRI, though repeated episodes leave behind permanent cortical thinning and atrophy. Patients typically experience visual disturbances, hemiparesis, aphasia, or cortical blindness during an episode, and seizures are extremely common, sometimes presenting as the first warning sign.

The mechanism behind stroke-like episodes likely involves nitric oxide deficiency. Nitric oxide is a signaling molecule that relaxes blood vessel walls and helps regulate cerebral blood flow. Mitochondrially dysfunctional endothelial cells in MELAS produce less nitric oxide than normal, impairing the local vasodilatory response when neural activity increases. When a region of cortex cannot vasodilate adequately to meet its energy demand during a period of heightened activity — triggered by fever, physiological stress, seizure, or sometimes no identifiable cause at all — local energy failure follows. This understanding of nitric oxide deficiency is the scientific basis for treating acute MELAS stroke-like episodes with L-arginine, the amino acid precursor to nitric oxide, which is described in the treatment section.

Full Clinical Spectrum

MELAS affects multiple organ systems simultaneously, and the full clinical picture extends well beyond the three features in the acronym. Lactic acidosis — an elevation in blood lactic acid caused by the shift from mitochondrial to anaerobic energy production — is often present at rest and worsens markedly with exercise. The ratio of lactate to pyruvate is elevated, reflecting impaired pyruvate oxidation. In some patients lactic acidosis is intermittent and may be missed on a single fasting blood draw; exercise provocation or cerebrospinal fluid lactate measurement during symptomatic periods improves detection. Chronically elevated lactic acid is reflected in elevated plasma alanine, which serves as a useful surrogate biomarker for ongoing mitochondrial dysfunction.

Seizures are present in the vast majority of MELAS patients and are often the most difficult symptom to control. Both focal seizures — particularly focal motor seizures and occipital seizures causing flashing lights or visual field loss — and generalized tonic-clonic seizures occur. Epilepsia partialis continua, a form of continuous focal motor seizure that can last hours to days, is seen in some patients during stroke-like episodes. Myopathy, meaning muscle disease, presents as proximal weakness and severe exercise intolerance out of proportion to muscle bulk. On muscle biopsy stained with Gomori modified trichrome, the characteristic "ragged red fibers" appear — clumps of abnormal mitochondria that have proliferated in a failing attempt to compensate for energy deficiency, pooling at the fiber edge and staining bright red. Cytochrome c oxidase (COX)-deficient fibers are also seen, reflecting the respiratory chain dysfunction.

Short stature affects many patients with MELAS and reflects the chronic energy deficiency during childhood development. Sensorineural hearing loss — progressive, bilateral, affecting high frequencies first — is among the most common features, present in a majority of m.3243A>G carriers even those who never develop stroke-like episodes. Cardiomyopathy affects approximately 20 to 30 percent of MELAS patients, and can be either hypertrophic (thickened heart walls) or dilated (weakened, enlarged heart). Wolff-Parkinson-White pre-excitation pattern and other cardiac conduction abnormalities are also reported. Eye involvement includes pigmentary retinopathy (abnormal deposits in the retina), ptosis (drooping eyelids), and ophthalmoparesis (weakness of the eye muscles), overlapping with features of Kearns-Sayre syndrome. Diabetes mellitus, discussed separately below, completes the picture of a truly multisystem disease.

MIDD: Maternally Inherited Diabetes and Deafness

A significant subset of people who carry the m.3243A>G mutation never develop the full triad of MELAS. Instead, they experience what is recognized as a distinct clinical syndrome called MIDD — maternally inherited diabetes and deafness. In MIDD, the mutation expresses itself primarily in two tissues: the insulin-secreting beta cells of the pancreas and the hair cells of the cochlea. The result is a combination of progressive sensorineural hearing loss and diabetes mellitus, typically appearing together in the same individual or across the same maternal family line. MIDD is estimated to account for approximately 0.5 to 2 percent of all type 2 diabetes diagnoses, making m.3243A>G the most common mitochondrial DNA mutation causing diabetes.

The diabetes in MIDD has several features that distinguish it from ordinary type 2 diabetes and that, if recognized, point toward the mitochondrial diagnosis. Onset tends to be younger, commonly in the 20s or 30s, rather than the typical middle-age or later presentation of type 2 diabetes. Patients are often lean rather than overweight, because the primary defect is in beta cell mitochondrial function rather than insulin resistance from adiposity. The family history, when traced carefully through the maternal line, reveals multiple relatives with diabetes, hearing loss, or both. Insulin dependence tends to develop faster than in typical type 2 diabetes, reflecting progressive beta cell loss.

One treatment decision in MIDD has critical safety implications: metformin, the first-line medication for ordinary type 2 diabetes, should be avoided in patients with mitochondrial disease. Metformin works in part by inhibiting mitochondrial respiratory chain complex I — which is already impaired in m.3243A>G carriers — and it raises the risk of lactic acidosis, sometimes to life-threatening levels. Patients with MIDD are typically managed with insulin, sulfonylureas, or SGLT2 inhibitors instead. Because the mutation is maternally inherited and all children of an affected mother are at risk, screening of all first-degree maternal relatives — checking fasting glucose, HbA1c, and audiometry — is recommended once the mutation is identified in a family member.

Diagnosis

Diagnosing MELAS requires assembling evidence from several different tests, because no single test tells the whole story. The first suspicion often arises when a young patient presents with a stroke-like episode, seizures, or progressive neurological decline combined with a maternal family history of similar problems, diabetes, or hearing loss. Blood lactate measured after a period of fasting, and again after mild exercise, is a useful screening test — elevated levels, particularly a lactate-to-pyruvate ratio above 20 to 25, point toward mitochondrial disease. When blood lactate is normal but symptoms are present, cerebrospinal fluid lactate measured by lumbar puncture is often elevated even when blood values are not. Plasma amino acids may show elevated alanine, a chronic marker of pyruvate excess.

MRI of the brain is essential and is often the most immediately informative test. The key finding is cortical T2/FLAIR hyperintensity that crosses vascular territories — most often in the occipital and parietal lobes — combined with restricted diffusion. Unlike ischemic stroke, MELAS lesions may shift between imaging sessions, partially resolve, and tend to spare the white matter preferentially. Basal ganglia T2 hyperintensities and calcification are seen in some patients. Serial MRI over years reveals progressive cortical atrophy and volume loss, particularly in previously affected regions. Brain MRI spectroscopy may show an elevated lactate peak in affected cortex.

Genetic testing for the m.3243A>G mutation is available from blood, but the tissue source matters enormously. In adults, blood heteroplasmy decreases with age because mutant mitochondria are selectively lost from rapidly dividing hematopoietic cells; blood testing may be falsely negative or underestimate the true burden. Urine sediment cells are preferred for adults because they retain higher and more representative mutant loads. Muscle biopsy provides the highest sensitivity and also allows direct measurement of respiratory chain enzyme activities (complexes I through IV) and morphological examination for ragged red fibers on Gomori trichrome staining and COX-deficient fibers. A cardiological evaluation including echocardiography and ECG is indicated in all patients to screen for cardiomyopathy and conduction abnormalities. Formal audiometry, ophthalmological assessment, glucose tolerance testing, and thyroid function tests round out the initial workup.

Treatment: Mitochondrial Cocktail and L-Arginine

There is currently no cure for MELAS and no treatment that corrects the underlying mitochondrial DNA mutation or restores normal respiratory chain function. Treatment is therefore divided into acute management of stroke-like episodes and seizures, chronic supplementation aimed at supporting mitochondrial function, and careful avoidance of agents that worsen mitochondrial disease. The most evidence-based acute intervention is intravenous L-arginine, the amino acid precursor to nitric oxide. In a landmark 2005 study by Koga and colleagues, IV L-arginine given during the acute stroke-like episode reduced the duration and severity of neurological deficits, and ongoing oral L-arginine supplementation reduced the frequency of future episodes. The rationale is straightforward: by supplying the nitric oxide synthesis pathway with its substrate, L-arginine helps restore vasodilatory capacity in mitochondrially dysfunctional endothelial cells, improving cerebral blood flow to ischemia-threatened cortex.

Citrulline, an amino acid that is converted to arginine in the body with better oral bioavailability than arginine itself, is an alternative or complement to oral L-arginine for ongoing prevention. Beyond arginine and citrulline, a "mitochondrial cocktail" of supplements is widely used in clinical practice, though the individual evidence base for each component varies. Coenzyme Q10 (CoQ10), at doses of 300 to 600 mg per day, is the most commonly used; it functions as an electron carrier in the respiratory chain and as a fat-soluble antioxidant. Riboflavin (vitamin B2, 100 to 400 mg per day) serves as a cofactor for complexes I and II and may be particularly beneficial in patients with complex I or II deficiency. Vitamin C, vitamin E, and alpha-lipoic acid are antioxidants that address the oxidative stress generated by impaired electron flow through dysfunctional respiratory chain complexes. Thiamine (vitamin B1) is sometimes added as a cofactor for pyruvate dehydrogenase. Carnitine may be supplemented to support fatty acid entry into the mitochondria, though it is less universally recommended than CoQ10 or riboflavin.

Seizure management in MELAS demands particular attention because one commonly used anti-epileptic drug — valproate — is absolutely contraindicated in mitochondrial disease. Valproate inhibits mitochondrial metabolism, depletes carnitine, and has caused fulminant hepatic failure in children with undiagnosed mitochondrial disease. Preferred anti-epileptic agents include levetiracetam, lamotrigine, and lacosamide. Dichloroacetate (DCA) reduces lactic acidosis by activating the pyruvate dehydrogenase complex, but a randomized controlled trial demonstrated that it caused a clinically significant peripheral neuropathy, limiting its long-term use. Hearing loss is managed with hearing aids and, when appropriate, cochlear implants. Diabetes is treated with insulin or sulfonylureas while avoiding metformin. Cardiac involvement is managed according to its specific form: pacemakers for conduction block, cardiac surgery if hypertrophic cardiomyopathy causes outflow obstruction, and standard heart failure therapy for dilated cardiomyopathy. Genetic counseling for the entire maternal family line is an essential component of care.

Prognosis and Living with MELAS

Prognosis in MELAS is highly variable and reflects the wide spectrum of disease severity driven by heteroplasmy. At one end, individuals who carry the m.3243A>G mutation at low heteroplasmy levels may experience only mild sensorineural hearing loss or maternally inherited diabetes, living normal lifespans with manageable symptoms. At the other end, patients with high mutant loads who develop full MELAS syndrome — with recurrent stroke-like episodes beginning in childhood or young adulthood — face a progressive decline. Each episode damages cortex that may not fully recover, leading over years to cumulative cognitive decline, memory impairment, and in some cases cortical blindness or severe dementia. Historically, median survival in severely affected MELAS was estimated in the mid-20s to 40s, though this figure is shifting upward with better understanding of the disease, earlier diagnosis, and more systematic supportive care.

Several physiological stressors are known to trigger or worsen stroke-like episodes and should be avoided wherever possible. Fasting creates an energy deficit that a mitochondrially compromised brain cannot buffer; patients should maintain regular meal schedules and never fast without medical supervision, particularly before surgical procedures. Fever substantially increases metabolic demand and should be treated aggressively with antipyretics; even a modest infection can trigger a stroke-like episode. Surgery poses risks on two fronts: the physiological stress of the procedure itself, and the choice of anesthetic agents. Propofol is particularly dangerous in mitochondrial disease — it can cause propofol infusion syndrome, a rare but often fatal complication linked to mitochondrial toxicity — and should be avoided. Anesthesiologists caring for MELAS patients should be informed of the diagnosis before any elective procedure so that alternative agents can be planned.

Living with MELAS, or caring for a family member who has it, involves navigating a disease that can affect virtually every organ system while remaining medically underrecognized. Many patients report years of diagnostic odyssey before the correct diagnosis was made, and the psychological burden of a progressive, incurable inherited disease is substantial. Support groups — particularly through the United Mitochondrial Disease Foundation (UMDF) and the Mitochondrial Disease Sequence Data Resource (MSeqDR) — provide community connection and access to up-to-date clinical guidance. Research interest in MELAS has intensified in recent years, with ongoing work on mitochondrial-targeted antioxidants, gene therapy approaches, and stem cell strategies. Clinical trials can be found through clinicaltrials.gov by searching for "MELAS" or "mitochondrial disease." While a cure remains in the research phase, the outlook for well-managed patients has improved meaningfully over the past two decades.

Key Research Papers

Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348(6302):651–653. PMID 2102678
Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16(4):481–488. PMID 6095216
Koga Y, Akita Y, Nishioka J, et al. L-Arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64(4):710–712. PMID 15728297
El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015;116(1–2):4–12. PMID 26095523
Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci. 2008;1142:133–158. PMID 18990125
Hirano M, Ricci E, Koenigsberger MR, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992;2(2):125–135. PMID 1422200
Haas RH. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120(6):1326–1333. PMID 18055683
Nesbitt V, Pitceathly RD, Turnbull DM, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation — implications for diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84(8):936–938. PMID 23355809
Majamaa K, Moilanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet. 1998;63(2):447–454. PMID 9683596
Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324–330. PMID 16476929
Ikawa M, Okazawa H, Kudo T, et al. Evaluation of mitochondrial dysfunction in vivo in MELAS and MERRF using (18)F-FDG PET. J Neurol Neurosurg Psychiatry. 2010;81(3):311–316. PMID 19726408
Mancuso M, Orsucci D, Angelini C, et al. The m.3243A>G mitochondrial DNA mutation and associated variable phenotypes. J Neurol. 2013;260(11):2726–2731. PMID 23851906